The Barcelona-based startup uses AI, IoT and real-time analytics to reduce errors, free up clinical staff time and improve efficiency, with US expansion planned alongside new partner Novanta.
Barcelona-based startup Health Lean Analytics (HLA) has raised €2.1 million funding, encompassing a €1.4 million seed financing round by several family offices— including Inderhabs, Namarel and Braincats — as well as a loan granted by the Spanish National Innovation Company (ENISA), a public entity under the Ministry of Industry, Trade and Tourism.
HLA specialises in automating data collection in hospital environments to reduce errors, free up clinical staff time, and improve the quality, safety, and sustainability of patient care.
The company develops solutions based on data automation, IoT, advanced analytics and AI, with a particular focus on the surgical suite, one of the most complex and critical environments within a hospital.
It enables the passive, automatic capture of clinical and operational data in real time, without manual intervention from healthcare staff, ensuring complete, reliable, and traceable information. In addition, its solutions integrate directly with existing hospital systems, unifying key data on patients, surgical materials, medications, operating room usage, and equipment and resource management.
Rather than simply displaying information, the platform interprets patterns, anticipates deviations and recommends concrete actions tailored to the needs of each role within the hospital. This enables reductions in operational and material costs, optimisation of surgical capacity, improvements in safety and quality of care, as well as freeing up clinical time and enhancing the experience of healthcare professionals.
This milestone has been made possible by the entry of Novanta as an advanced technology and strategic partner. Novanta’s advanced manufacturing and medical technology expertise, and their access to the US marketplace will enable HLA to address this new phase of growth and validate its technology in a highly demanding environment. Novanta will have representation on HLA’s Board of Directors.
“The incorporation of Novanta as an advanced technology partner validates our technological and strategic strength and provides us with the resources and expertise needed to accelerate our R&D innovation,” says Mauro Batesteza, co-founder and co-CEO.
“With this support, we will be able to initiate commercial deployment in the United States, a key market, and demonstrate how our technology transforms hospital management by increasing efficiency, safety and quality of patient care..”
John Lesica, Co-Chief Operating Officer of Novanta, states, “HLA has built a compelling AI and data analytics platform that transforms complex hospital operations into real-time, actionable intelligence. What excites us at Novanta is the convergence: our RFID and sensing technologies capture the data that powers HLA’s AI engine. Together, we’re closing the loop between physical hospital workflows and intelligent decision-making — a combination with the potential to fundamentally change how hospitals operate, starting with one of their most critical environments: the operating room.”
The funds will be used to accelerate the company’s international expansion, with the United States as the first strategic market and a commercial deployment planned over the next 12 months, and to further strengthen its R&D capabilities.